feed,title,long_url,short_url
Benzinga,"Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment",https://benzinga.com/general/biotech/22/11/29787736/gene-editing-stocks-prospects-cut-in-half-by-analyst-citing-limited-value-in-retina-treatment,https://bit.ly/3Xg0O5z
Benzinga,Credit Suisse Sets Bearish Tone For Amgen; Says Current Setup Not Ideal For Growth,https://benzinga.com/analyst-ratings/analyst-color/22/11/29788708/credit-suisse-sets-bearish-tone-for-amgen-says-current-setup-not-ideal-for-growth,https://bit.ly/3VdAg3j
Benzinga,"Alibaba Will Be Critical Beneficiary Of China's Reopening and Economic Recovery, Analysts Say",https://benzinga.com/analyst-ratings/analyst-color/22/11/29786918/alibaba-will-be-critical-beneficiary-of-chinas-reopening-and-economic-recovery-anal,https://bit.ly/3Xg0OCB
